Analysis of the new round of launch price of osimertinib/osimertinib

Osimertinib (Osimertinib) is an oral targeted therapy drug, mainly used to treat EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC).

The original drug of Osimertinib/Osimertinib has been officially sold in China and has also been included in the national medical insurance system, so domestic patients can easily purchase it. Currently, the price of this drug in China is approximately RMB 3,000 to 4,000, but for the specific price and reimbursement status of medical insurance, patients are advised to consult their local hospital pharmacy to obtain the most accurate information.

In comparison, the prices of foreign generic drugs are more affordable. In particular, the price of generic drugs on the market in Laos and Bangladesh is generally only around a few hundred yuan, which is far lower than the domestic price. It is worth mentioning that these generic drugs maintain a high degree of consistency in drug ingredients with the original drugs, providing patients with a more economical treatment option.

Osimertinib/Osimertinib is a third-generation EGFRtyrosine kinase inhibitor that blocks the growth, proliferation and metastasis of tumor cells by inhibiting the activity of the EGFR signaling pathway, thereby inhibiting the development of tumors.

Osimertinib/Osimertinibis suitable for EGFRgene mutation-positive advanced NSCLC patients, especially those who are resistant to other EGFR inhibitors. For those who have Del19, L858R or T790Metc.

Osimertinib/OsimertinibCommon adverse reactions include rash, diarrhea, drowsiness, fatigue, cough, etc. Serious adverse reactions may include interstitial pneumonia, cardiovascular events, visual impairment, etc. Patients should pay close attention to their own conditions during medication and report any symptoms of discomfort to their doctors in a timely manner.

In general, osimertinib/osimertinib, as a targeted therapy, has high selectivity and efficacy, providing an effective treatment option for EGFRgene mutation-positive advanced NSCLC patients. Patients should strictly abide by the doctor's instructions during medication and report any adverse reactions in a timely manner to ensure the safety and effectiveness of treatment.